The same pharmacogenomics that sits on our condition pages, read from the other end. People rarely arrive asking about SLCO1B1 — they arrive having been prescribed a statin. Each page below collects what published guidelines say about one drug, names the genes involved, and links to the variants your own file would contain.
Supplements — kept apart, with the evidence stated on each →
None of this is dosing guidance. Where a clinical guideline exists it is written for prescribers, and the pages say so. Nothing here is a reason to start, stop or change a medication.
The example everyone reaches for when they want to show that pharmacogenomics changed practice — and it did. Test before the first dose, do not prescribe if positive, and a reaction people used to fear became rare.
HLA-B
See what the research says → AntiretroviralThe only entry here where the consequence is entirely cosmetic and entirely consequential: visible jaundice that harms nobody, and makes people stop taking a drug that was working.
UGT1A1
See what the research says → AntiretroviralA standard dose can put several times the intended amount of drug into somebody who clears it slowly, and what follows — vivid dreams, dizziness, trouble concentrating — is the commonest reason people stop.
CYP2B6
See what the research says →The same pharmacogenomics already published on our condition pages, read from the drug side instead: what published guidelines say about one medicine, which genes are involved, and the variants your own file would contain.
No. Where a clinical guideline exists it is written for prescribers, and nothing here is a reason to start, stop or change a medication — that belongs with the clinician or pharmacist managing treatment.
Because almost nothing sold as a supplement has a prescribing guideline behind it the way a drug does, and listing the two together would lend the second the authority of the first.
By gene symbol as a whole word, gathered from the pgx_notes already published on the condition pages that discuss each drug — not a second, separate copy of that information.